Search

Your search keyword '"Prupas, H"' showing total 14 results
Start Over Author "Prupas, H"
14 results on '"Prupas, H"'

1. Tenidap in Rheumatoid Arthritis: A 24-Week Double-Blind Comparison with Hydroxychloroquine-Plus-Piroxicam, and Piroxicam Alone

Author

Blackburn, Warren D., Prupas, H. Malin, Silverfield, Joel C., Poiley, Jeffrey E., Caldwell, Jacques R., Collins, Ronald L., Miller, Michael J., Sikes, David H., Kaplan, Herbert, Fleischmann, Roy, Scoville, Craig D., Rutstein, Joel E., Hurd, Eric R., Louie, James S., Bankhurst, Arthur D., Weaver, Arthur L., Sebba, Anthony I., Appelrouth, Daniel J., Hudson, Norman P., Gordon, Gary V., Gordon, Richard D., Ludivico, Charles L., Austin, Mitchell C., Sanders, Karen M., Schuette, Patrick T., Moidel, Robert A., Kraska, Allen R., Ting, Naitee, Shanahan, William R., and Loose, Leland D.

Published
1995

2. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

Author

Tak, Pp, Rigby, Wf, Rubbert Roth, A, Peterfy, Cg, van Vollenhoven RF, Stohl, W, Hessey, E, Chen, A, Tyrrell, H, Shaw, Tm, Aelion J, IMAGE I. n. v. e. s. t. i. g. a. t. o. r. s., Afif, N, Ahmadi, F, Aires, F, Alanis, E, Alonso, Cs, Alten, Rh, Alvaro Gracia JM, Ashrafzadeh, A, Ballina, J, Bambara, Lm, Bao, C, Bell, M, Berney, S, Bessette, L, Birbara, C, Boling, E, Bourgeois, P, Braun, J, Briones, H, Brzezicki, J, Burgos Vargos, R, Burmester, G, Burnett, M, Busch, H, Cabello, E, Calvo, A, Cantagrel, A, Cantini, F, Zea, Ac, Carreño Perez, L, Chavez, J, Shim, Sc, Chindalore, V, Chiriac, R, Codding, C, Danda, D, Del Guidice, J, De Vita, S, Digiovanni, R, Dikranian, A, Eider, W, Fantini, F, Ferraccioli, G, Fietchner, J, Filipowicz Sosnowska, A, Finnanger, B, Fiocco, G, Fleck, M, Fleischmann, R, Fraser, A, Gaudin, P, Gauler, G, Gaylis, N, Gerlag, Dm, Godde, J, Gomez Reino JJ, Gornisiewicz, M, Gough, W, Greenwald, M, Guerra, G, Hackshaw, K, Haentzschel, Hm, Hammond, T, Hazleman, Bl, Heilig, B, Herenius, Mm, Hilliquin, P, Holt, D, Huang, F, Huff, J, Huizinga, T, Isaacs, J, Jaffer, A, Amante, Ej, Jeka, S, Jimenez, R, Jones, G, Jones, R, Kaine, J, Kashif, A, Kaufmann, C, Kay, J, Khraishi, M, Kivitz, A, Klinkhoff, A, Kraag, G, Krystufkova, O, Kucharz, E, Lawson, J, Leirisalo Repo, M, Levin, R, Liang, G, Liang, P, Limonta, M, Lowenstein, M, Rodriguez Lozano, C, Lue, C, Mahowald, M, Maradiaga, M, Maricic, M, Mariette, X, Martin, L, Massarotti, E, Matucci Cerinic, M, Montecucco, Cm, Mazurov, V, Mcnally, J, Mehta, D, Meyer, O, Misra, R, Moreland, Lw, Mueller Ladner, U, Myerson, G, Nasonov, E, Navarra, S, Navarro, F, Neal, N, Olech, E, Olsen, N, Pablos, Jl, Pacheco, C, Pal, S, Palomo, Er, Pandith, V, Penserga, Eg, Prupas, H, Radominski, S, Ramos Remus, C, Reid, D, Riordan, K, Rosenberg, D, Ruiz, A, Saadeh, C, Salvarani, Carlo, Samuels, A, Sanmarti, R, Sarzi Puttini, P, Saxe, P, Schechtman, J, Scoville, C, Sedlackova, M, Sedrish, M, Sejer Hansen, M, Sibilia, J, Siebert, S, Specker, C, Stern, S, Szechinski, J, Tahir, H, Taylor, A, Thompson, Pw, Tony, Hp, Tornero, J, Trapp, R, Tremblay, Jl, Valesini, G, Van Den Bosch, F, Wanchu, A, Wassenberg, S, Ximenes, Ac, Kim, Hy, Zanetakis, E, Zazueta, B, Zerbini, C., Faculteit der Geneeskunde, AII - Amsterdam institute for Infection and Immunity, Clinical Immunology and Rheumatology, and Other departments

Subjects
Adult, musculoskeletal diseases, medicine.medical_specialty, Adolescent, Immunology, 610 Medizin, Arthritis, Severity of Illness Index, Gastroenterology, Drug Administration Schedule, General Biochemistry, Genetics and Molecular Biology, law.invention, Arthritis, Rheumatoid, Antibodies, Monoclonal, Murine-Derived, Young Adult, Double-Blind Method, Rheumatology, Randomized controlled trial, law, immune system diseases, Internal medicine, medicine, Clinical endpoint, Humans, Immunology and Allergy, heterocyclic compounds, skin and connective tissue diseases, Aged, Aged, 80 and over, ddc:610, business.industry, Middle Aged, medicine.disease, Surgery, Clinical trial, Methotrexate, Treatment Outcome, Antirheumatic Agents, Rheumatoid arthritis, Disease Progression, Drug Therapy, Combination, Rituximab, business, medicine.drug
Abstract

Objectives: Rituximab is an effective treatment in patients with established rheumatoid arthritis (RA). The objective of the IMAGE study was to determine the efficacy of rituximab in the prevention of joint damage and its safety in combination with methotrexate (MTX) in patients initiating treatment with MTX. Methods: In this double-blind randomised controlled phase III study, 755 MTX-naïve patients with active RA were randomly assigned to MTX alone, rituximab 2×500 mg + MTX or rituximab 2×1000 mg + MTX. The primary end point at week 52 was the change in joint damage measured using a Genant-modified Sharp score. Results: 249, 249 and 250 patients were randomly assigned to MTX alone, rituximab 2×500 mg + MTX or rituximab 2×1000 mg + MTX, respectively. At week 52, treatment with rituximab 2×1000 mg + MTX compared with MTX alone was associated with a reduction in progression of joint damage (mean change in total modified Sharp score 0.359 vs 1.079; p=0.0004) and an improvement in clinical outcomes (ACR50 65% vs 42%; p

Published
2011

3. Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study

Author

MEASE, PHILIP J., primary, WEI, NATHAN, additional, FUDMAN, EDWARD J., additional, KIVITZ, ALAN J., additional, SCHECHTMAN, JOY, additional, TRAPP, ROBERT G., additional, HOBBS, KATHRYN F., additional, GREENWALD, MARIA, additional, HOU, ANTONY, additional, BOOKBINDER, STEPHEN A., additional, GRAHAM, GALEN E., additional, WIESENHUTTER, CRAIG W., additional, WILLIS, LARRY, additional, RUDERMAN, ERIC M., additional, FORSTOT, JOSEPH Z., additional, MARICIC, MICHAEL J., additional, DAO, KATHRYN H., additional, PRITCHARD, CHARLES H., additional, FISKE, DARRELL N., additional, BURCH, FRANCIS X., additional, PRUPAS, H. MALIN, additional, ANKLESARIA, PERVIN, additional, and HEALD, ALISON E., additional

Published
2009
Full Text
View/download PDF

4. Tenidap in Patients with Rheumatoid Arthritis

Author

Prupas, H. M., primary, Loose, L. D., additional, Spindler, J. S., additional, Dietz, A. J., additional, Gum, O. B., additional, Weisman, M. H., additional, Gordon, G., additional, Wolf, R. E., additional, Turner, R. A., additional, Collins, R. L., additional, Germain, B. F., additional, Katz, P., additional, Ballou, S. P., additional, Wolfe, F, additional, Daniels, J. C., additional, April, P. A., additional, Willkens, R. F., additional, Pariser, K., additional, Hepburn, B., additional, Zizic, T. M., additional, Ting, N., additional, and Mehrban, M., additional

Published
1996
Full Text
View/download PDF

5. Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study

Author

MEASE, PHILIP J., WEI, NATHAN, FUDMAN, EDWARD J., KIVITZ, ALAN J., SCHECHTMAN, JOY, TRAPP, ROBERT G., HOBBS, KATHRYN F., GREENWALD, MARIA, HOU, ANTONY, BOOKBINDER, STEPHEN A., GRAHAM, GALEN E., WIESENHUTTER, CRAIG W., WILLIS, LARRY, RUDERMAN, ERIC M., FORSTOT, JOSEPH Z., MARICIC, MICHAEL J., DAO, KATHRYN H., PRITCHARD, CHARLES H., FISKE, DARRELL N., BURCH, FRANCIS X., PRUPAS, H. MALIN, ANKLESARIA, PERVIN, and HEALD, ALISON E.

Abstract

OBJECTIVE: To assess safety and clinical outcomes in patients with inflammatory arthritis after intraarticular (IA) injection of rAAV2-TNFR:Fc, a recombinant adeno-associated viral vector containing the human tumor necrosis factor (TNF) receptor-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene. METHODS: In this phase 1/2 randomized study, adults with persistent moderate or severe inflammation in a target joint, being treated with or without systemic anti-TNF therapy, received a single IA injection of either rAAV2-TNFR:Fc (1 x 1011, 1 x 1012, or 1 x 1013DNase-resistant particles/ml joint volume) or placebo, followed by open-label rAAV2-TNFR:Fc 12–30 weeks later, depending on when the target joint met predetermined criteria for reinjection. RESULTS: 127 subjects received the first injection of blinded study drug; 95 subjects received open-label rAAV2-TNFR:Fc. Administration site reactions, consisting of transient mild to moderate increases in tenderness and swelling of the injected joint, occurred after 23/191 (12%) rAAV2-TNFR:Fc injections and were dose-dependent. Rates of other adverse events were not dose-dependent. Notable serious adverse events (SAE) included culture-negative septic arthritis in a subject receiving leflunomide and fatal disseminated histoplasmosis considered unrelated to rAAV2-TNFR:Fc in a subject receiving adalimumab. In the phase 2 portion of the study, a 30% decrease in target joint global visual analog scale was observed in 21/50 (42%) rAAV2-TNFR:Fc subjects and 3/16 (19%) placebo subjects 12 weeks after first injection (p = 0.14). CONCLUSION: IA rAAV2-TNFR:Fc resulted in administration site reactions after 12% of injections. A fatal SAE, disseminated histoplasmosis, was considered not related to study agent. Patient-reported outcome measures of clinical response showed greater improvement in treated patients than placebo patients.

Published
2010

7. Emphysema secondary to tonsillectomy.

Author

Malin Prupas, H. and Fordham, Stewart D.

Abstract

An unusual complication of tonsillectomy is tissue emphysema and/or pneumomediastinitis. A patient is described with both of these conditions, which probably resulted directly from the introduction of air into the tonsillar bed either during the surgical procedure itself or in the postoperative recovery period. The possible etiologies and recognition of this problem are discussed. [ABSTRACT FROM AUTHOR]

Published
1977
Full Text
View/download PDF

12. Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.

Author

Prupas HM

Subjects
Female, Gold Sodium Thiomalate therapeutic use, Humans, Middle Aged, Syndrome, Synovitis drug therapy, Cerebrovascular Disorders chemically induced, Gold Sodium Thiomalate adverse effects, Vasomotor System drug effects
Abstract

Vasomotor reactions after gold sodium thiomalate are well recognized. When they do occur they are rarely a clinical problem. We describe a 50-year-old woman with rheumatoid arthritis in whom a severe postinjection vasomotor reaction was associated with a cerebral vascular accident.

Published
1984

13. Acute idiosyncratic reaction to hydrochlorothiazide ingestion.

Author

Prupas HM and Brown D

Subjects
Adult, Female, Humans, Leukopenia chemically induced, Thrombocytopenia chemically induced, Hydrochlorothiazide adverse effects, Hypertension drug therapy, Pulmonary Edema chemically induced
Published
1983

Catalog

Books, media, physical & digital resources
See catalog results